ResMed | RMD - Ebitda



金融业
股票价格
USD
资产
USD 8.78B
现金及等价物
USD 1.66B
销售成本
USD 540.43M
流动资产
USD 4.06B
流动负债
USD 1.35B
债务
USD 843.17M
股息收益率
USD 1.04
EBIT
USD 499.81M
EBITDA
USD 568.84M
员工
USD 8.16K
EPS每股收益
USD 0.27
股本和储备
USD 6.49B
销售毛利
USD 890.98M
债务利息支出
USD 775K
利息收入
USD 59K
贷款资金
USD 404.17M
市值
USD 33.17B
净收入
USD 398.73M
营业费用
USD 931.6M
营业利润
USD 499.81M
普通股股本
USD 145.04M
PE价格收益
21.77
税前利润
USD 502.31M
销售收入
USD 1.43B
销售和管理费用
USD 285.66M
股票
USD 911.88M
贸易债权人
USD 273.3M
应收帐款人
USD 1.05B


Ebitda 更改 日
Ansell USD 185.8M 7M 2025-12
Avita Medical AUD -9.69M 12.21M 2025-12
Cochlear AUD 306.4M 13.5M 2025-12
CSL USD 3.13B 1.17B 2025-12
Fisher & Paykel Healthcare NZD 434M 70M 2026-06
Healius AUD 74.9M 40.3M 2025-06
Integral Diagnostics AUD 46.27M 3.52M 2024-06
Mayne Pharma AUD 20.9M 5.2M 2025-06
Nanosonics AUD 12.49M 1.13M 2025-12
Polynovo AUD 3.89M 100K 2025-12
Ramsay Health Care AUD 1.12B 10.6M 2025-12
Regis Healthcare AUD 70.59M 12.81M 2025-12
ResMed USD 568.84M 21.36M 2026-03
Sigma Healthcare AUD 19.96M 5.15M 2024-07
Sonic Healthcare AUD 839.07M 51.09M 2024-12
Telix Pharmaceuticals AUD 76.49M 58.07M 2026-06